Merck's CETP inhibitor meets in CV outcomes study
Merck & Co. Inc. (NYSE:MRK) said cholesteryl ester transfer protein (CETP) inhibitor anacetrapib (MK-0859) significantly reduced major coronary events in the Phase III REVEAL study, meeting its primary endpoint. Compared with placebo, anacetrapib significantly reduced a composite of coronary death, myocardial infarction and coronary revascularization.
The trial evaluated anacetrapib given daily in about 30,000 patients receiving effective LDL-lowering treatment with atorvastatin for a median duration of at least four years and at high risk of cardiovascular events. ...
BCIQ Target Profiles